ABT.SW Abbott (SIX) CHF100.00 intraday: earnings 22 Jan 2026 could shift outlook
ABT.SW stock trades at CHF100.00 intraday as investors position ahead of Abbott Laboratories’ earnings due 22 Jan 2026. The upcoming report will test diagnostics demand and device sales, two core drivers of Abbott’s Healthcare segment. Traders should note the stock’s PE 15.70 and EPS 6.37, which frame expectations for any guidance change. We review valuation, short-term technical cues, and how results could move the SIX-listed Abbott (Switzerland) listing.
Earnings snapshot: ABT.SW stock and near-term catalysts
Abbott (ABT.SW) reports results on 22 Jan 2026 and markets expect clarity on diagnostics and device revenue. The company lists on the SIX exchange in Switzerland and the release is an intraday catalyst for volume and price. Ahead of the print the stock is at CHF100.00 with a year high of CHF106.00. Investors should watch revenue mix, margin trends, and management commentary for guidance changes.
Financials and valuation metrics for ABT.SW stock
Abbott shows a trailing PE 15.70 and EPS of 6.37, implying steady earnings power versus the Healthcare peer group. Market cap stands near CHF173.89B and dividend yield is about 1.94%. The company posts a return on equity of 28.24% and free cash flow per share of 3.95. These metrics support a neutral-to-positive valuation ahead of earnings.
Meyka AI rates ABT.SW with a score out of 100 and model outlook
Meyka AI rates ABT.SW with a score out of 100: 71.74 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, and analyst consensus. The score is informational only and not financial advice. Our forecasts show short-term variance: the monthly model is CHF98.19, the quarterly model is CHF110.78, and the yearly model is CHF91.69. These projections reflect earnings sensitivity and are model-based.
Technical view and intraday trading cues for ABT.SW stock
Intraday momentum is muted while the Relative Strength Index sits near 39.74. Average price over 50 sessions is CHF99.24 and 200-day average is CHF102.26, suggesting mixed medium-term bias. Traders should watch volume spikes at the open and after the earnings release for directional confirmation. A close above CHF106.00 would reassert the year high resistance.
Earnings sensitivity: price targets and scenario analysis for ABT.SW stock
We set scenario price targets to map outcomes. Conservative target CHF90.00 (implied -10.00% vs CHF100.00). Base target CHF105.00 (implied +5.00%). Bull case CHF115.00 (implied +15.00%). These targets incorporate diagnostics momentum, device cycle strength, and the current PE 15.70 valuation. Use them as reference points, not guarantees.
Risks and sector context affecting ABT.SW stock
Key risks include weaker diagnostic volumes and margin pressure in medical devices. Exposure to global supply chains and competitive pricing also matters. The Healthcare sector on SIX shows an average PE near 33.75, which places Abbott below sector multiples and gives room for re-rating if results beat. Currency moves and US market dynamics can influence the Switzerland-listed price.
Final Thoughts
Meyka AI’s forecast model projects mixed near-term outcomes for ABT.SW stock. The model gives a monthly projection of CHF98.19 (-1.81% vs CHF100.00), a quarterly projection of CHF110.78 (+10.78%), and a yearly projection of CHF91.69 (-8.31%). Abbott’s trailing PE 15.70 and EPS 6.37 leave the stock fairly valued versus many Healthcare peers, but earnings detail on 22 Jan 2026 can shift sentiment. Our scenario price targets range from CHF90.00 to CHF115.00, reflecting downside and upside paths tied to diagnostics demand and device sales. Forecasts are model-based projections and not guarantees. Watch post-earnings guidance, margin language, and volume cues on the SIX listing to judge whether the market moves toward the base or bull target.
FAQs
When does Abbott (ABT.SW) report earnings?
Abbott (ABT.SW) announces earnings on 22 Jan 2026. Expect results to cover revenue, margins, and forward guidance that can affect short-term trading of ABT.SW stock.
What is the current price and valuation for ABT.SW stock?
ABT.SW stock trades at CHF100.00 intraday with a trailing PE 15.70 and EPS 6.37. These figures suggest a moderate valuation versus the Healthcare sector on SIX.
What price targets should investors consider for ABT.SW stock?
Scenario targets: conservative CHF90.00, base CHF105.00, bull CHF115.00. Use targets as reference points tied to earnings surprises and guidance shifts for ABT.SW stock.
How reliable are Meyka AI forecasts for ABT.SW stock?
Meyka AI’s forecasts are model-based projections and not guarantees. They combine financials, trends, and sector data to estimate ABT.SW stock paths; always complement them with company filings and analyst notes.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
